---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-22-000079"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:04:02.468718+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024

## Summary
- Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.
- Net loss of $14.7M for Q2 2022 vs. $10.7M in Q2 2021; cash, equivalents & investments $334.9M.
- Platform launch (instruments and reagents) targeted for mid-2024; early access revenue starting early 2024.
- Anticipates cash runway extending well into 2025.
- Hired Eric Spence (VP Instrument Engineering) and Ken Kuhn (VP Reagent & Process Development).

## SEC filing metadata
- accession: 0001808805-22-000079
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/0001808805-22-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/naut-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-22-000079
- JSON: https://secwatch.observer/filing/0001808805-22-000079.json
- Plain text: https://secwatch.observer/filing/0001808805-22-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.